IMMUNOPHENOTYPIC DESCRIPTION OF PATIENTS WITH A MYELODYSPLASTIC SYNDROME AND 2 SPECIFIC CYTOGENETICS ABNORMALITIES: DELETION OF 5Q AND TRISOMY 8

被引：0
|
作者：
Subira, M. [1 ]
Font, P. [2 ]
Arranz, E. [3 ]
Serrano, C. [1 ]
Gonzalo, R. [1 ]
Castanon, S. [1 ]
Mata, R. [1 ]
Soto, C. [1 ]
Olaso, E. [4 ]
Roman, A. [1 ]
Lamas, P. L. [1 ]
机构：
[1] Fdn Jimenez Diaz, E-28040 Madrid, Spain
[2] Clin Moncloa, Madrid, Spain
[3] Gemolab Lab, Madrid, Spain
[4] Clin Santa Elena, Madrid, Spain
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0719
引用
收藏
页码：289 / 289
页数：1
相关论文
共 50 条
  • [21] Routes of Clonal Evolution into Complex Karyotypes in Myelodysplastic Syndrome Patients with 5q Deletion
    Feurstein, Simone
    Thomay, Kathrin
    Hofmann, Winfried
    Buesche, Guntram
    Kreipe, Hans
    Thol, Felicitas
    Heuser, Michael
    Ganser, Arnold
    Schlegelberger, Brigitte
    Goehring, Gudrun
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (10)
  • [22] A paediatric myelodysplastic syndrome with 5q deletion associated with Fanconi anaemia
    Kornreich, Laure
    Soulier, Jean
    Grange, Beatrice
    Girard, Sandrine
    Ouchee-Chardin, Marie
    Ceraulo, Antony
    PEDIATRIC BLOOD & CANCER, 2020, 67 (07)
  • [23] 2 KARYOTYPICALLY UNRELATED CLONES WITH THE T(5, 17) AND DELETION OF 5Q IN MYELODYSPLASTIC SYNDROME
    NOVAK, A
    JANKOVIC, G
    ROLOVIC, Z
    CANCER GENETICS AND CYTOGENETICS, 1992, 62 (01) : 100 - 102
  • [24] Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion
    Ximeri, Maria
    Galanopoulos, Athanasios
    Klaus, Mirjam
    Parcharidou, Agapi
    Giannikou, Krinio
    Psyllaki, Maria
    Symeonidis, Argyrios
    Pappa, Vasiliki
    Kartasis, Zafiris
    Liapi, Dimitra
    Hatzimichael, Eleftheria
    Kokoris, Styliani
    Korkolopoulou, Penelope
    Sambani, Constantina
    Pontikoglou, Charalampos
    Papadaki, Helen A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (03): : 406 - 414
  • [25] TELOMERE SHORTENING AND AML PROGRESSION IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AND DELETION 5Q TREATED WITH LENALIDOMIDE
    Goehring, G.
    Lange, K.
    Hofmann, W.
    Buesche, G.
    Kreipe, H.
    Hellstroem-Lindberg, E.
    Giagounidis, A.
    Schlegelberger, B.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 378 - 379
  • [26] Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomide
    Eclache, Virginie
    Da Rocha, Anna
    Le Roux, Genevieve
    Fenaux, Pierre
    HAEMATOLOGICA, 2008, 93 (02) : 315 - 316
  • [27] Paediatric Myelodysplastic Syndrome With 5Q Deletion in a Patient With Hyperleukocytosis and Significant Lymphadenopathy
    Coopasamy, K.
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S458 - S459
  • [28] Myelodysplastic syndromes with a deletion 5q display a characteristic immunophenotypic profile suitable for diagnostics and response monitoring
    Oelschlaegel, Uta
    Westers, Theresia M.
    Mohr, Brigitte
    Kramer, Michael
    Parmentier, Stefani
    Sockel, Katja
    Thiede, Christian
    Bornhaeuser, Martin
    Ehninger, Gerhard
    van de Loosdrecht, Arjan A.
    Platzbecker, Uwe
    HAEMATOLOGICA, 2015, 100 (03) : E93 - E96
  • [29] Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer
    B L Ebert
    Leukemia, 2009, 23 : 1252 - 1256
  • [30] Azacitidine Treatment of Lenalidomide-Resistant Myelodysplastic Syndrome with Deletion 5q
    Komrokji, Rami S.
    Al Ali, Najla H.
    Padron, Eric
    Lancet, Jeffrey E.
    List, Alan F.
    BLOOD, 2011, 118 (21) : 1195 - 1195
12345